That is what makes the Digital Health & AI Innovation Summit (DHAI), taking place June 8-9 in Boston, distinctive within an increasingly competitive field of AI and innovation conferences. The Summit certainly offers a high-caliber program and noted speakers. However, its real value proposition beyond the agenda lies in the conversations and takeaways.

The carefully curated forum, organized by Amir Lahav, PhD, and World BI, is intentionally designed for a smaller community of roughly 500 attendees and more than 150 speakers and innovators. The result is that the connections become as valuable as the presentations.

That distinction matters more than many realize.

Artificial intelligence and digital health are moving at extraordinary speed. Health systems, pharmaceutical companies, regulators, investors and technology innovators are all trying to answer the same questions: How do we apply innovation responsibly while improving outcomes for patients and clinicians? How do we integrate AI into the R&D process? How can we leverage information technologies to accelerate the recruitment of the right people for clinical trials? The challenge is no longer simply technological capability. The challenge is implementation, governance and integration into the realities of care delivery.

Those questions are difficult to answer from the back row of a ballroom.

They are more likely to be explored over coffee between sessions, during a shared meal, or in quieter moments when people can challenge assumptions, exchange experiences and discuss what is actually working in health systems, research environments, and patient care settings.

That is where DHAI distinguishes itself.

The Power of Curated Expertise

What gives a conference enduring value is not only the quality of its speakers, but whether those speakers remain accessible enough to challenge assumptions, answer difficult questions and engage in unscripted dialogue. That is increasingly uncommon in modern health conferences, where influence often feels managed from a distance.

At DHAI, the proximity to the experience of 150 presenters is intentional.

The next era of health won’t be built in silos and it certainly won’t be forged by focusing on the hype. It requires leaders willing to share their failures alongside their successes, and their fears alongside their visions,” shares Amir Lahav, PhD, curator and DHAI organizer. “The DHAI Summit provides an exclusive, trusted space for these unfiltered conversations that rarely happen on public stages. This is an exclusive invitation to join the health AI  pioneers who are moving the needle and step into the room where the real trajectory of medicine is being shaped,” he adds.

For attendees seeking to understand how artificial intelligence is moving from experimentation to clinical reality, few conversations may prove more valuable than those surrounding the work of Dr. Dennis Wall at Stanford University. His groundbreaking efforts to apply AI to accelerate diagnostics, particularly in neurological and developmental conditions, reflect the growing intersection of machine learning and patient-centered medicine. In most settings, hearing someone like Wall speak might last 20 minutes. Here, the opportunity to continue the discussion between sessions may be equally important as the presentation itself.

The same can be said for leaders shaping the future of pharmaceutical innovation through AI. Thomas Fuchs, Chief AI Officer at Eli Lilly and Company, operates at the center of one of the most significant transformations underway in life sciences. His work integrating AI, pathology and drug discovery reflects how computational science is redefining therapeutic development. With pharmaceutical companies investing billions into AI-enabled research ecosystems, the ability to exchange perspectives directly with someone navigating those realities daily carries extraordinary value.

Precision medicine also takes on a more practical dimension through leaders such as John Axerio-Cilies, Chief Data and Technology Officer at Tempus AI. Tempus has become emblematic of how data science, oncology and artificial intelligence are beginning to reshape personalized medicine and diagnostics. Yet the real insight often comes not from keynote slides but from candid reflections on implementation challenges, physician adoption, workflow integration, and trust in AI-driven systems.

What also distinguishes the program is its recognition that health innovation no longer lives within traditional boundaries. Biology, computational science, organizational leadership and entrepreneurship are rapidly converging, creating entirely new expectations for how innovation enters the health ecosystem.

That reality becomes especially clear when considering trusted voices such as Tom Lawry, author of Hacking Healthcare and one of the most respected global advisors on AI strategy in health. For years, Lawry has argued that artificial intelligence alone cannot transform the delivery of care. Institutions themselves must evolve alongside technology. Leadership structures, workflow, culture and decision-making all become part of the innovation equation. His perspective reinforces an increasingly important truth: AI implementation is not fundamentally a technology challenge. It is a human challenge.

That same intersection between innovation and execution is reflected in the participation of Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups. Her work focuses on helping emerging companies move beyond promising ideas toward scalable and commercially viable solutions. Through strategy development, technical enablement and go-to-market support, she works directly with startups navigating the increasingly complex realities of AI, digital health and life sciences innovation. At a time when thousands of companies are entering the AI marketplace, Frank brings an unusually practical understanding of what separates experimentation from sustainable impact across the global health ecosystem.

The scientific and technical dimensions of the Summit are equally compelling. Arturo Loaiza-Bonilla, MD, MSEd, Co-Founder and Chief Medical AI Officer of Massive Bio, Network Chief of Hematology and Oncology at St. Luke’s University Health Network, whom I met recently during HITLAB Health Innovation Week in New York, champions an important evolution in medicine, where clinical leadership, oncology, data science and AI innovation are interconnected. His work sits at the intersection of precision medicine, clinical trials and responsible AI application, demonstrating how technology can expand access and support informed care decisions while keeping physicians and patients at the center of the experience.

The program also grounds innovation in the realities of patient care and health system operations. Through her leadership at NYC Health + Hospitals, Dr. Komal Bajaj has focused extensively on quality, equity and implementation within one of the nation’s largest public health systems. Her perspective introduces an important layer of realism into discussions that can sometimes become overly theoretical. AI may promise efficiency, but health systems must still ensure that innovation improves care delivery rather than complicates it.

That balance between aspiration and practicality is also reflected in leaders such as Lauren Li of Novartis, whose work in AI and innovation strategy demonstrates how global life sciences companies are integrating AI responsibly across research, development, and commercialization. The questions facing companies like Novartis are no longer whether AI will shape health innovation, but how to apply it responsibly while preserving scientific rigor and public trust.

Equally important to the DHAI agenda is the presence of Jeremy Walsh, Chief AI Officer at the Food and Drug Administration. At a moment when AI is moving rapidly into research, clinical decision support, diagnostics and operational health systems, regulatory leadership must provide oversight. FDA voice addresses a growing concern that innovation and governance cannot operate on separate tracks. The future of AI in health will depend not only on technological capability, but on transparency, accountability and safety. His perspective brings a policy and regulatory dimension to a conversation too often dominated by technology.

Taken together, these leaders represent more than expertise. They reflect the convergence of medicine, data science, biotechnology, health systems, patient engagement and policy. The global health ecosystem is entering a period in which barriers between disciplines are dissolving. Clinicians must understand data science. Technologists must better appreciate patient experience and the realities of workflow. Pharmaceutical leaders must think beyond molecules toward digital ecosystems and longitudinal patient engagement.

Why Human Connection Still Matters in the AI Era

That convergence changes the value of gatherings like this one. Large conferences often showcase these worlds side by side. Smaller curated forums create the possibility for those worlds to interact.

That dynamic is particularly important in digital health, where enthusiasm can sometimes outpace evidence. AI is neither a miracle nor a menace. It is a tool shaped by human intention, data quality and leadership. The most important conversations in AI and health today are not only about capability. They are about judgment.

How do we reduce physician burnout without depersonalizing medicine? How do we use predictive analytics responsibly? How do we ensure that innovation improves access rather than deepens disparities? How do we maintain trust while integrating increasingly autonomous technologies into patient care?

Those are conversations that require candor and mutual learning.

As someone attending and stepping to the stage during DHAI, I believe that may ultimately become its greatest differentiator. In health, relationships still matter. Communication still matters. Shared perspective still matters. Technology may accelerate insight, but human interaction remains essential to wisdom.

Health innovation does not advance through presentations alone. It advances through collaboration, challenge and conversation. Those exchanges between sessions often become the catalyst for strategies and unexpected ideas that continue long after this event comes to a close.

In a global health environment often defined by complexity, there is growing value in spaces where innovation feels ambitious and human. The DHAI appears designed to deliver that ROI.

The post The Value of Health AI Conferences Is No Longer the Stage. It’s the Hallway Conversation appeared first on Medika Life.

CCI’s approach is designed to support rapid advancement of ambitious research in complex scientific and medical fields. Focusing initially on neuroscience and systems biology, and the convergence of these multidisciplinary areas facilitated through innovative technologies, CCI will help further ambitious projects that improve health and well-being for all. Examples include the development of a novel therapeutic approach leveraging neuro-inspired AI systems, and CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to engineer entire ecosystems. 

“Despite major advances in recent decades, global health and access to quality care has not sufficiently improved and in some cases is actually declining. Solving these challenges requires scientific rigor and exploration of complex, interconnected systems that underpin human health. The classic reductionist approach to R&D viewed these as distinct scientific disciplines to be studied in isolation,” said Caleb B. Bell III, PhD, President and Executive Director of CCI. “We are empowering scientists and innovators to take a new approach to today’s biggest challenges, supported by a global ecosystem of like-minded individuals. With a systems biology, non-reductionist mindset, groundbreaking insights can rapidly translate into viable solutions that improve global health and well-being.”

The CCI model represents a fundamental shift in how scientific research is funded, developed and translated globally. By identifying high-potential researchers early in their careers and providing them with dedicated, long-term resources, CCI enables scientists and innovators to explore ambitious projects without the constraints of short-term thinking. The CCI team has cultivated a collaborative, global network of thought leaders in science, business, and finance to help innovators overcome obstacles and accelerate progress.

“Corundum Convergence Institute is building a platform where groundbreaking science is not only supported but also stewarded with a clear pathway to societal benefit,” said Yasushi Yamamoto, CEO of Corundum Corp. “By integrating resources and leveraging expertise from across the Corundum network, we are positioning CCI to be a critical force in bridging cutting-edge research with real-world impact, laying the foundation for a new era in health innovation.”

Corundum Convergence Institute is an independently governed entity, created by fellow Corundum Corp venture builders and funds Corundum Neuroscience and Corundum Systems Biology, with the specific mission of funding early-stage scientific research in the fields of neuroscience, systems biology and artificial intelligence.

About Corundum Convergence Institute (CCI)

Corundum Convergence Institute (CCI) is a non-profit organization committed to advancing transformative research at the frontiers of neuroscience, systems biology, and artificial intelligence. By focusing on early-stage innovation in complex, high-impact fields, CCI supports the development of products and technologies leading to paradigm shifts in healthcare, including novel therapeutic approaches to neuro-inspired AI and improved diagnostics for neurodegenerative and metabolic conditions. CCI’s multidisciplinary approach fosters convergence across fields, enabling scientists and entrepreneurs to explore the intersections of science, human biology and advanced technology in ways that will fundamentally reshape health and wellbeing. As part of the greater Corundum network, CCI offers a creative path to translate bold scientific ideas to real-world impact.

For company updates and information, follow Corundum Convergence Institute on LinkedIn or visit https://cci-fund.org.

The post Corundum Convergence Institute Launches to Catalyze Funding for Research and Innovation in Neuroscience and Systems Biology appeared first on Medika Life.

While San Francisco certainly has a historical impact on global health innovation, the Boston health ecosystem is fertile ground to be the nation’s power hub for innovation, research, and economic growth. Boston has emerged as a key player – perhaps the place – in the life science sector with its world-class universities, renowned hospitals, and investment community. Innovation accelerates when talent, infrastructure, and finance converge on a geographic area. 

Boston’s concentration of top-tier academic institutions, including Harvard University, MIT, and Tufts Medical School, attract brilliant minds worldwide, leading to groundbreaking discoveries and pioneering research in biotechnology, devices, genomics, and pharmaceuticals. These innovations applied to patient care have improved health outcomes and fostered collaborations between academia and industry, driving innovation and the development of life-saving therapies.

Employment Opportunities Abound in Boston

The Massachusetts Biotechnology Education Foundation’s “2023 Massachusetts Life Sciences Employment Outlook” reports that the life sciences sector in Massachusetts is home to 132,000 jobs. This study predicts another 42,000 new jobs will come online in 10 years.

The presence of world-class hospitals and community safety nets like Boston Medical Center, Massachusetts General Hospital and Brigham and Women’s Hospital offer scaled and start-up biotech, contract research organizations, digital health, medical device and pharmaceutical companies a base to listen, learn and apply. These institutions attract top medical talent, providing a foundation for companies to tap into great minds as advisors on the practical issues facing innovators – how to navigate the fragmented US health ecosystem – even how to recognize revenue.

Not at BIO, but at another nearby life science digital health meeting. Barry Finette, MD, Ph.D., founder of ThinkMD, a physician, who has worked around the world in emergency medicine, is among those who have transitioned from full-time medicine to the innovation sector reflects why change is so urgent:

“The US has the most sophisticated high-quality healthcare in the world if you can afford it and have access to it. For too many Americans, neither is the case. The US healthcare system is in crisis, even though we spend more on healthcare per person per year (>$11K) than any other country in the world, and yet, the US is ranked in the 20-30s in the world for most key health indices and have a life expectancy that has been decreasing.”

Beyond BIO, Digital Health Leaders Meet at the Digital Healthcare Innovation Summit to Explore Needed Changes

The Digital Healthcare Innovation Summit 2023 (#DHIS2023 and #DHISEast) meeting is a hidden gem.  Though the meeting rooms are packed, this annual gathering held in Boston still needs to be discovered.  Its attendees and speakers represent the health ecosystem of decision-makers who must learn more about each other’s business agenda – how their models work and thrive economically.

The unscripted panel sessions almost guarantee that the mainstage conversationalists will “tell it like it is.” The speakers are drivers of change and include Sree Chaguturu, MD, chief medical officer of CVS; Christopher Brooker, partner, Frist Cressey Ventures; Magann Vaughn Watters, vice president, New Ventures & Strategic Alliances, LabCorp; Tarun Mehra, vice president, Healthcare Strategy, M&A and Partnerships, Microsoft.  The impressive list of speakers and attendees reinforces the value of this gathering – more so – it underscores the power of Boston as a microcosm of the national health system and its possibilities.

[Photo: Moderator Nancy Brown, General Partner, Oak HC/FT explores with panelists Neel Shah, MD, CMO, Maven Clinic; Lori Evans Bernstein, Co-Founder & CO, Caraway; Angela Glyder, VP, Clinical Operations, Lucina Analytics, and Sukanya L. Sonderland, senior vice president Blue Cross Blue Shield of Massachusetts, on “Women, Families, and Health – Understanding the Market, Its Impact and How You Measure Success”]

The Summit jumped into pressing access to-care challenges – sometimes conflicts – facing the US health system. CVS’s Chaguturu outlined the retail pharmacy giant’s strategy around the acquisition of Oak Street Health and the evolution of its Minute Clinic model. CVS has also invested in Maven Health to improve greater access to women’s health.

Maven Women’s Health founder and CEO Kate Ryder smartly outlined how this unicorn enterprise has succeeded by focusing on its customers’ – women’s health – needs rather than enticing tech platforms.  Maven has built one of the more comprehensive platforms providing support across fertility, pregnancy, adoption, parenting, and pediatrics. The company received the Digital Healthcare Innovator – East Coast Award.

Boston – A Model for Harmonious Health Innovation and Navigating the Health Ecosystem

“Culture crushes change,” reflects health innovation theorist John Nosta, president of Nosta Labs.  Too many significant changes that might help heal the disjointed health ecosystem fail – not because the invention will not improve people’s care – it doesn’t mesh with the system’s economic sensibilities.  The greater Boston region may be part of the treatment for failure.

Listening to the speakers at #DHIS2023, it’s noticed that many of the leaders on the stage and conference room are not engineers; they are rooted within the medical system. Some are trained health professionals and others work within the health system – they are part of a closed-loop community and seek collaboration. 

Instead of bemoaning the interference of AI and ChatGPT, they imagine how these technologies can integrate successfully into their workflow. Instead of looking for ways to reject ideas that will change the care process, they are rolling up their sleeves to figure out how to untangle the links in the supply chain of patient care.

If BIO is the place to explore business development and partnerships, DHIS is the forum for experts in the trenches of digital and health tech to transparently examine how all this work comes together as the system seeks to change.

We’ll be back in Boston later this month to explore how these leaders will change the future of health innovation development through diversity in clinical trials.  Stay tuned.

The post Life Science Dominates Boston in June as BIO (and DHIS) Take Over Bean Town appeared first on Medika Life.